logo
Resources
Therapy Services
(970)682-1582

In-Person and Telehealth Medicine

Adult, Adolescent, and Child Psychiatrist located in Fort Collins, CO
misc image

Medication Management services offered in Fort Collins, CO


Psychiatric Services offers medication management for a variety of conditions, including:

• Depression
• Bipolar Disorder
• Anxiety
• ADHD
• OCD
• PTSD

Medication Management Q&A

Psychiatric Services of the Rockies offers a variety of options for medication management. Below are answers to questions you may have regarding the service. For further questions or to book an appointment, please call our office at (970)682-1582. 

Do you offer telehealth?
Yes, we offer in-person office visits and telehealth options for medication management. 

Do you off medication management for children?
Yes, we offer psychiatric services for ages 5 and up. 

My pharmacy has not received my prescription. What do I do?
Please call our office at (970)682-1582 if you suspect you pharmacy did not receive your prescription.

Will you accept my insurance?
Please call our office at (970)682-1582 for any questions regarding coverage for your treatment.

Can I receive treatment if I do not have insurance?
We offer self-pay and out-of-pocket options for individuals without health insurance. Please call our office at (970)682-1582 for more information.

WHAT WE OFFER

SPRAVATO®

Spravato® (esketamine) is an FDA-approved treatment for adults with treatment-resistant depression (TRD) and for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. Unlike traditional antidepressants that primarily target serotonin and norepinephrine, Spravato works through the glutamate system as an NMDA receptor antagonist. This mechanism allows it to promote rapid synaptic plasticity and restore neural connectivity in mood-regulating circuits, often leading to improvement much faster than standard oral antidepressants.

Clinical trials have demonstrated that Spravato, when used in combination with an oral antidepressant, produces significant reductions in depressive symptoms compared to oral antidepressant therapy alone. Many patients experience noticeable improvement within hours to days, particularly in severe cases. In treatment-resistant depression, response rates in clinical studies have ranged from approximately 50–70%, with a substantial proportion achieving remission. These outcomes are especially meaningful for individuals who have failed multiple prior medication trials.

Treatment is administered intranasally in a monitored medical setting to ensure safety and effectiveness. Because Spravato can cause temporary dissociation, sedation, or increases in blood pressure, patients are observed for approximately two hours after each session. The treatment protocol typically includes twice-weekly sessions during the induction phase (first 4 weeks), followed by weekly or biweekly maintenance sessions depending on clinical response and stability.

For individuals who have struggled with persistent depression despite multiple medication trials, Spravato represents a powerful and evidence-based option. By targeting the underlying neurobiology of depression through a novel pathway, it offers hope for meaningful and sustained symptom relief, improved functioning, and restored quality of life.

More